New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
- Authors: Laktionov KK1, Reutova EV1, Nelyubina LA1, Pitkevich MY.1, Okruzhnova MA1, Ardzinba MS1, Yudin DI1, Demidova IA2, Zaretsky AR3,4
-
Affiliations:
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- Moscow City Oncological Hospital No.62
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS
- Eurogen Lab
- Issue: Vol 20, No 2 (2018)
- Pages: 50-54
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29551
- DOI: https://doi.org/10.26442/1815-1434_2018.2.50-54
- ID: 29551
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
K K Laktionov
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием хирургическим №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E V Reutova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: marenich.al@yandex.ru
канд. мед. наук, ст. науч. сотр. отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
L A Nelyubina
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
M Yu Pitkevich
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationврач-ординатор отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
M A Okruzhnova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, врач-онколог отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
M S Ardzinba
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, врач-онколог отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
D I Yudin
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. отд-ния хирургического №13 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
I A Demidova
Moscow City Oncological Hospital No.62Department of Health of Moscow 143423, Russian Federation, Moskovskaia obl., Krasnogorskii raion, pos. Istra, d. 27, str. 1-26
A R Zaretsky
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS; Eurogen Labканд. мед. наук, науч. сотр. ФГБУН ИБХ РАН, рук. отд. молекулярной онкологии 117997, Russian Federation, Moscow, GSP-7, ul. Miklukho-Maklaia, d.16/10
References
- Mok T.S, Wu Y.L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10): 947-57.
- Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25): 2380-88.
- Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3): 239-46.
- Miller V.A, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2B/3 randomised trial. Lancet Oncol 2012; 13 (5): 528-38.
- Arcila M.E, Oxnard G.R, Nafa K, Riely G.J et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid- based assay. Clin Cancer Res 2011; 17: 1169-80.
- Kobayashi S, Boggon T.J, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
- Pao W, Miller V.A, Politi K.A et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
- Yu H.A, Arcila M.E, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
- Bean J, Brennan C, Shih J.Y et al. MET amplifica-tion occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932.
- Sequist L.V, Waltman B.A, Dias-Santagata D. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3, 75ra26.
- Ross Camidge D, Pao W, Lecia V. Sequist Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473-81.
- Ward R.A, Anderton M.J, Ashton S. et al. Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). J Med Chem 2013; 56: 7025-48. PubMed: 23930994
- Chih-Hsin Yang J et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017; 35 (12): 1288-96.
- Goss G, Tsai C.M, Shepherd F.A et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17 (12): 1643-52. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.
- Mok T.S, Yi-Long Wu et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376: 629-40. doi: 10.1056/NEJMoa1612674
- Oxnard G.R, Thress K.S, Alden R.S et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34 (jco.ascopubs.org on June 29, 2016)
- Douillard J.Y, Ostoros G, Cobo M et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9: 1345-53.
- Mok T, Wu Y.L, Lee J.S et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: a randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). J Thorac Oncol 2013; 31. (Suppl: Abstract 8021).
- Punnoose E.A, Atwal S, Liu W, Raja R et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trialof pertuzumab and erlotinib. Clin Cancer Res 2012; 18: 2391-401.
- Sun J.M, Karlovich C, Wen W et al. Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686, Mol. Cancer Ther 2013; 12 (Suppl Abstract B25).